Recent Posts
The IN VIVO Blog
Return To Blog Listing
News, insight and analysis on the business of the biopharmaceutical industry from the editors of Windhover Information and FDC Reports, publishers of IN VIVO and "The Pink Sheet".
Recent Posts Tagged With 'financing'
And the Exit/Financing Deal of the Year Nominees Are ...
OK readers, it's time to have your say! This year we've set up a special IVBDOTY web page where you can vote in all three categories. CLICK HERE TO GO TO THE VOTING BOOTH.And so here, in no particular order, are your IN VIVO Blog 2009 Exit/Financin...
2009 Exits/Financings DOTY Nominee: Movetis\' IPO
It's time for the IN VIVO Blog's Second Annual Deal of the Year! competition. This year we're presenting awards in three categories--that's 300% more fake prizes than last year!--to highlight the most interesting and creative deal making solutions of...
Financings of the Fortnight Needs a Top-Up
Sometimes, we need a little extra. Know what we mean?A little extra sleep--just five more minutes... Maybe just one more beer, sure. OK just one more holiday cookie ... an extra day to finish the 'Financings of the Fortnight' post. But this past coup...
Do We Have the Right Managers for the UK Innovation Investment Fund?
The UK government yesterday announced that Hermes Private Equity and the European Investment Fund (EIF) had been selected to manage the technology-focused UK Innovation Investment Fund (IIF).Science & Innovation Minister Lord Drayson reckons the ...
Financings of the Fortnight’s Pot Luck Supper vs Food for Thought from Tauzin and Kindler
This week we’ve got a little bit of everything out there for you FOTFanatics. Corporate Venture? Of course. Meaty FOPO? You got it. Odd restructuring? Why not. Sexy SEDA? Your wish is our command. And unlike last fortnight’s Eurolicious entourage...
Financings of the Fortnight Has European Flavor, Movetis Roadshow Fever
Gas up, everyone, it's time for a European road trip. First stop, Turnhout, Belgium, where gastrointestinal biopharma Movetis is gearing up for a trip of its own.This morning the Belgian J&J spin-out said it filed to raise up to more than €112 ...
Corporate VCs Star In Financings Of The Fortnight
Oh, venture capitalists. After Dow Jones released its third quarter investment numbers for venture capital two weeks ago, we decided to mine our database to see if all flavors of vc--traditional and strategic--were equally affected. It wasn't terribl...
California More Generous Than Expected With Stem-Cell Money
CIRM, the California agency in charge of research and development funding of stem-cell related work, is awarding $225 million to 14 preclinical projects, it said this morning. That's nearly $60 million more than its scientific reviewers recommended.W...
Financings of the Fortnight is Mr October, But VC Funding Off in Q3
Life sciences VCs, like the defending World Series champion Philadelphia Phillies, tend to rely on the long-ball. Unlike those Fightin’ Phils (who, in case you missed it, are on their way to a second straight Fall Classic courtesy of a four-home-ru...
Financings of the Fortnight: Appetite for Risk?
Cash continues to flow into biotech offerings big and small. On the large side, Elan and UCB each raised money through debt offerings--Elan pulled in $625 million through the sale of senior fixed rate notes due in 2016 and UCB raised €500 million f...
Vertex: What's a Biodollar Worth, Ctd.
A few months after announcing that its European telaprevir milestones were up for sale, Vertex said last night that it had signed a deal--actually a two-part deal--that would net it $155 million for the future payments from J&J.Oddly it's the sec...
Financings of the Fortnight Is the One They Call Dr. Feelgood
For this fortnight's financing highlights we've selected a motley crew of creative deals that aren't your typical financing fodder, some real Live Wires. Huge anonymous private investments, dilution-sparing CEFFs, royalty monetization, massive mezzan...
Financings of the Fortnight: PIPEing Hot Returns?
The deal that Norwegian biotech Algeta signed with Bayer last week for its Phase III Alpharadin bone metastases candidate sent its shares soaring. The stock spiked to NOK83, closing the day on an all-time high of NOK56.The investors in Algeta's Febru...
Financings of the Fortnight: Throwing in the Towel?
Amidst the general thirst out there for capital to support R&D we can think of one biotech that isn't itching to get into IVB's Financings of the Fortnight: Cardiome.Four-and-a-bit months on from their $60 million up-front deal with Merck & ...
Financings of the Fortnight: Follow-On Fever
This week's IPOs from Cumberland Pharmaceuticals and Emdeon may have garnered all the headlines. But for portents of a future biotech IPO market--as opposed to a market in IPOs for profitable, less risky companies like Cumberland and Emdeon--look ins...
Health Care IPOs: Is that A Breeze?
Just one day after Cumberland Pharmaceuticals priced its shares, Emdeon followed suit, setting industry watchers abuzz. Could it be it's time to resurrect the acronym IPO? (Just in case you need a reminder, it's pronounced 'eye-pee-oh' and stands fo...
Cumberland's IPO: Is It the Day After the Day After Tomorrow?
Well, well, Mr. IPO. It has certainly been a while. You don't call, you don't write ...Cumberland Pharmaceuticals said late last night that it priced 5 million shares at $17 apiece for a gross haul of $85 million (the company will net closer to $75 m...
Financings of the Fortnight: Summer Madness
Welcome to a new regular post on IN VIVO Blog where we'll do our best to analyze the biopharma fundraising scene on an every-other-week basis, paying special attention to a handful of deals that particularly float our collective boats or are indicati...
What's a Biodollar Worth? Let's Ask Vertex
Vertex announced this morning that it intended to sell (to an unnamed buyer) its future milestone payments associated with the filing, approval and launch of telaprevir in Europe.Those milestones would be paid out by J&J, which licensed European ...
Notes from BIO: Toast of the Coast--Incubator vs. Pfincubator
While an earlier session on raising capital in trying times was cancelled--as if to say "yes, it really is that bad!"--it was standing room only at yesterday morning's last-day session titled “Early Stage Investment Strategies: If Not Us, Who? If N...
Notes from BIO: The Times, They Are a Changin'
"We’ve become the last or second last round investors, where as we used to be shunned from the pre-IPO rounds. Eight, nine years ago we weren’t part of the party. We were kicked out whenever we wanted to play." --Howie Furst, Deerfield PartnersTh...
Has PE-Backed Pharma R&D Risk Hedging Fizzled?
This morning we learned that former AstraZeneca CFO and current Goldman Sachs partner Jon Symonds (right) is leaving that bank to join Novartis as CFO-designate. Symonds will take the financial reins at the Swiss pharma next April, when current CFO R...
